Shandong Boan Biotechnology Co (FRA:UJ9) LT-Debt-to-Total-Asset: 0.08 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UJ9 Shandong Boan Biotechnology Co Ltd FRA:UJ9
39 GF Score
Price €0.61
GF Value €1.72
! 5 Warning Signs
View Full Analysis

What is Shandong Boan Biotechnology Co LT-Debt-to-Total-Asset?

Shandong Boan Biotechnology Co FRA:UJ9 +6.14% 39 LT-Debt-to-Total-Asset is 0.08 as of Dec. 2025. GuruFocus rates FRA:UJ9 with a GF Score™ of 39/100 and a GF Value™ of €1.72. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Shandong Boan Biotechnology Co's long-term debt to total assests ratio for the quarter that ended in Dec. 2025 was 0.08.

Shandong Boan Biotechnology Co's long-term debt to total assets ratio declined from Dec. 2024 (0.15) to Dec. 2025 (0.08). It may suggest that Shandong Boan Biotechnology Co is progressively becoming less dependent on debt to grow their business.

Shandong Boan Biotechnology Co  (FRA:UJ9) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Shandong Boan Biotechnology Co LT-Debt-to-Total-Asset Related Terms

Shandong Boan Biotechnology Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Shandong Boan Biotechnology Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Boan Biotechnology Co LT-Debt-to-Total-Asset Chart

Shandong Boan Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 0.12 0.10 0.10 0.15 0.08

Shandong Boan Biotechnology Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.10 0.19 0.15 0.11 0.08
FRA:UJ9
39GF Score
Shandong Boan Biotechnology Co Ltd FRA:UJ9
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Boan Biotechnology Co LT-Debt-to-Total-Asset Calculation

Shandong Boan Biotechnology Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=38.029/500.241
=0.08

Shandong Boan Biotechnology Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (Q: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2025 )/Total Assets (Q: Dec. 2025 )
=38.029/500.241
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.08 mean?
Shandong Boan Biotechnology Co (FRA:UJ9) has a LT-Debt-to-Total-Asset of 0.08 as of Dec. 2025. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Shandong Boan Biotechnology Co and its competitors.
Is Shandong Boan Biotechnology Co's LT-Debt-to-Total-Asset too high?
Shandong Boan Biotechnology Co's current LT-Debt-to-Total-Asset is 0.08. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's LT-Debt-to-Total-Asset compare to VRTX and REGN?
Shandong Boan Biotechnology Co's LT-Debt-to-Total-Asset of 0.08 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Shandong Boan Biotechnology Co and its competitors. Shandong Boan Biotechnology Co's current LT-Debt-to-Total-Asset is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Shandong Boan Biotechnology Co (FRA:UJ9) has a current LT-Debt-to-Total-Asset of 0.08. The stock's GF Value™ is €1.72, compared to a current price of €0.61 — trading 64.8% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.08. Shandong Boan Biotechnology Co's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (FRA:UJ9), the current LT-Debt-to-Total-Asset is 0.08 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Boan Biotechnology Co (FRA:UJ9) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued. The current stock price of €0.61 is trading 64.8% below its estimated GF Value™ of €1.72.

Key valuation signals for FRA:UJ9:

  • LT-Debt-to-Total-Asset: 0.08
  • GF Value™: €1.72 vs. price of €0.61 (64.8% below fair value)
  • GF Score™: 39/100 with 5 warning signs

No single metric tells the full story. See the FRA:UJ9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shandong Boan Biotechnology Co Business Description

Other Exchanges 06955:Hong Kong
Address No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
39GF Score

Get the complete analysis for FRA:UJ9

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.61
Price
€1.72
GF Value